The latest

News

Charles Tait Graves

How Startups Can Minimize Risk in the Area of Trade Secrets

“Any nonpublic item of business information that could be valuable to a competitor is a trade secret,” Graves said. “Business details, product roadmaps, financial information, customer information, if it’s not public and if it would be useful for a competitor, it can be a trade secret. It doesn’t have to be strictly scientific and technical information.”

Latest news3

Audience in the Bakar Bio Labs auditorium

Lunch & Learn with Levitree and Equator Therapeutics

On Wednesday, at our first our first Lunch and Learn for 2025, the founders of Levitree and Equator Therapeutics came to present their work and their teams, giving the greater Bakar Bio Labs community a better sense of what they do. Read post
Marco Lobba, Rachel Haurwitz, and Wei Wu

Event Recap: “Working With Strategic Investors”

“Between all these investors and companies,” Haurwitz said, “I think it becomes very clear over time that different incentives drive different interactions.” She advises building personal relationships to find out how and why each fund makes investments: some for profit, some for strategic reasons (like licensing or later acquisition); sometimes both at the same fund. (Haurwitz was the first student to work on CRISPR in Jennifer Doudna’s lab, she said; traditional VCs had no interest in CRISPR while CVCs – Dupont first among them – were knocking on the door, quick to see the long-term potential.) Read post